Xilio Therapeutics director Rachel Humphrey resigns, to stay as consultant

Xilio Therapeutics, Inc.

Rachel Humphrey, M.D. resigned from Xilio's board effective February 3, 2022.
Resignation was not due to any disagreement with the company or its management.
Dr. Humphrey will continue to serve as a consultant to Xilio Therapeutics.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Rachel Humphrey

director

XLO · Xilio Therapeutics, Inc.

Effective: 2022-02-03
Filed: February 4, 2022, 6:59 PM ET

On February 3, 2022, Rachel Humphrey, M.D. notified Xilio Therapeutics, Inc. (the “Company”) of her decision to resign from the board of directors of the Company effective as of such date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Rachel Humphrey resigned as director at Xilio Therapeutics, Inc..

Action: resigned
Role: director

Exact text from the filing

On February 3, 2022, Rachel Humphrey, M.D. notified Xilio Therapeutics, Inc. (the “Company”) of her decision to resign from the board of directors of the Company effective as of such date.

View on SEC.gov

Xilio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-22-000789

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.